Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial

Publication | Closed Access

DOI

130

Citations

References

2023

Year

Chantal Mathieu, Björg Ásbjörnsdóttir, Harpreet S. Bajaj, Wendy Lane, Ana Laura de Souza Almeida Matos, Sreenivasa Murthy, Karolina Stachlewska, Julio Rosenstock

The Lancet

Diabetes ManagementInsulin ManagementDiabetesClinical TrialsOnce-weekly InsulinNon-inferiority TrialDiabetes MellitusInsulin DeliveryPhase 3AMedicine